" class="no-js "lang="en-US"> Rich Happell - Medtech Alert
Monday, June 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Richard Happell

Rich Happell

About Rich Happell

Over 16 years of experience with the Life Science Industry. Prior positions include engineering, distribution, procurement, product management, Sales, Sales Management, Business management, Global Sourcing, and Sales Director.

Specialties: Conducting International Business, Sales, Marketing, Balanced perspective with operational and commercial experience

Related Story

Companies

 CELLTREAT Acquires VistaLab Technologies | Pharmtech Focus

CELLTREAT Acquires VistaLab Technologies

March 24 2022

CELLTREAT® Scientific Products (“CELLTREAT”) and VistaLab™ Technologies (“VistaLab”) today announced the execution of a definitive agreement under […]